What the Bulks List is
The 503B Bulks List is FDA's list of bulk drug substances that 503B FDA-registered outsourcing facilities are permitted to use as starting materials. A substance must either be on the Bulks List or have a documented clinical need for compounding from bulk for a specific patient.
Semaglutide, tirzepatide, and liraglutide have been on or implicitly accepted on the Bulks List during the shortage window. FDA's April 30, 2026 notice proposes to formally exclude them, citing the closure of the shortage exception and the availability of FDA-approved versions.
What this would change
If finalized, 503B outsourcing facilities would no longer be able to compound GLP-1 medications from bulk API as a standard practice. They could still compound from FDA-approved drug source under narrower exceptions, but at substantially higher input cost.
The practical effect is to constrain — though not eliminate — the 503B side of compounded-GLP-1 supply. Programs that route the majority of their volume through 503B for cost reasons would either reroute to 503A patient-specific compounding (lower throughput, higher unit cost) or exit compounded supply.
What it would not change
The 503A patient-specific compounding pathway is governed by different statutory language and is not gated by the 503B Bulks List. 503A pharmacies can continue to compound GLP-1 medications on a patient-specific basis under the standard documented-medical-necessity framework that applies post-shortage.
Providers that already disclose 503A pathways for patient-specific prescriptions — NexLife being the cleanest example in the 2026 ranking — would be largely unaffected. Providers that rely heavily on 503B batch supply would need to reroute or contract their offerings.